Anthony J. Recupero Sells 3,310 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN - Get Free Report) insider Anthony J. Recupero sold 3,310 shares of the company's stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $18.27, for a total transaction of $60,473.70. Following the completion of the transaction, the insider owned 279,121 shares in the company, valued at $5,099,540.67. This trade represents a 1.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

SiBone Trading Up 1.8%

NASDAQ SIBN traded up $0.34 during trading on Thursday, hitting $18.78. The company had a trading volume of 294,940 shares, compared to its average volume of 393,604. The company has a current ratio of 8.53, a quick ratio of 7.26 and a debt-to-equity ratio of 0.21. SiBone has a one year low of $11.70 and a one year high of $20.05. The company has a market cap of $800.40 million, a price-to-earnings ratio of -29.34 and a beta of 0.93. The company's fifty day moving average is $18.17 and its 200-day moving average is $16.29.

SiBone (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.09. The company had revenue of $47.29 million for the quarter, compared to the consensus estimate of $45.13 million. SiBone had a negative net margin of 15.03% and a negative return on equity of 16.00%. On average, sell-side analysts predict that SiBone will post -0.78 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on SIBN. Needham & Company LLC restated a "buy" rating and issued a $24.00 price target on shares of SiBone in a research report on Tuesday, May 6th. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price target on shares of SiBone in a research report on Tuesday, May 6th. Finally, Truist Financial lifted their price objective on shares of SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th.

Institutional Investors Weigh In On SiBone

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Proficio Capital Partners LLC purchased a new position in SiBone during the fourth quarter worth $155,000. Charles Schwab Investment Management Inc. grew its stake in shares of SiBone by 2.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 321,263 shares of the company's stock worth $4,504,000 after acquiring an additional 6,171 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in SiBone in the fourth quarter valued at approximately $1,233,000. AlphaQuest LLC lifted its holdings in SiBone by 13,950.6% in the fourth quarter. AlphaQuest LLC now owns 11,662 shares of the company's stock valued at $164,000 after acquiring an additional 11,579 shares during the period. Finally, Essex Investment Management Co. LLC raised its stake in shares of SiBone by 24.3% during the 4th quarter. Essex Investment Management Co. LLC now owns 208,160 shares of the company's stock worth $2,918,000 after buying an additional 40,636 shares during the period. Institutional investors own 98.11% of the company's stock.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.